Ratios (Summary)

Biogen Inc., profitability ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Return on Sales
Gross profit margin 86.72% 87.08% 88.48% 87.93% 87.63%
Operating profit margin 43.54% 44.99% 45.44% 40.94% 36.29%
Net profit margin 20.69% 32.34% 32.95% 30.25% 26.87%
Return on Investment
Return on equity (ROE) 20.13% 30.50% 37.84% 27.15% 21.60%
Return on assets (ROA) 10.73% 16.19% 18.19% 20.50% 15.70%

Source: Based on data from Biogen Inc. Annual Reports

Ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Biogen Inc.'s gross profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Biogen Inc.'s operating profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Biogen Inc.'s net profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.
ROE A profitability ratio calculated as net income divided by shareholders' equity. Biogen Inc.'s ROE deteriorated from 2015 to 2016 and from 2016 to 2017.
ROA A profitability ratio calculated as net income divided by total assets. Biogen Inc.'s ROA deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Gross Profit Margin

Biogen Inc., gross profit margin calculation

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Gross profit 10,643,900  9,970,100  9,523,400  8,532,288  6,074,473 
Revenues 12,273,900  11,448,800  10,763,800  9,703,324  6,932,199 
Ratio
Gross profit margin1 86.72% 87.08% 88.48% 87.93% 87.63%
Benchmarks
Gross Profit Margin, Competitors
Abbott Laboratories 47.75% 54.09% 54.19% 51.73% 50.43%
AbbVie Inc. 75.05% 77.25% 80.31% 77.83% 75.62%
Allergan PLC 86.40% 87.23% 68.08% 51.74% 45.94%
Amgen Inc. 81.33% 80.99% 79.82% 77.12% 81.61%
Bristol-Myers Squibb Co. 70.80% 74.54% 76.39% 75.24% 71.81%
Celgene Corp. 96.45% 96.08% 95.41% 94.90% 94.65%
Eli Lilly & Co. 73.46% 73.35% 74.76% 74.85% 78.76%
Gilead Sciences Inc. 82.97% 85.77% 87.54% 84.52% 73.54%
Johnson & Johnson 66.84% 69.84% 69.27% 69.40% 68.67%
Merck & Co. Inc. 68.16% 65.10% 62.19% 60.30% 61.50%
Pfizer Inc. 78.61% 76.66% 80.25% 80.69% 81.42%
Regeneron Pharmaceuticals Inc. 93.24% 93.83% 90.43% 92.73% 92.62%

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × 10,643,900 ÷ 12,273,900 = 86.72%

Ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Biogen Inc.'s gross profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Operating Profit Margin

Biogen Inc., operating profit margin calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Income from operations 5,344,200  5,150,400  4,891,000  3,972,414  2,515,509 
Revenues 12,273,900  11,448,800  10,763,800  9,703,324  6,932,199 
Ratio
Operating profit margin1 43.54% 44.99% 45.44% 40.94% 36.29%
Benchmarks
Operating Profit Margin, Competitors
Abbott Laboratories 6.30% 15.27% 14.05% 12.84% 12.03%
AbbVie Inc. 33.99% 36.60% 32.97% 17.09% 30.14%
Allergan PLC -37.15% -12.53% -20.00% -9.71% -4.88%
Amgen Inc. 45.76% 44.74% 40.44% 32.03% 32.25%
Bristol-Myers Squibb Co. 17.39% 23.83% 11.41% 16.32% 18.90%
Celgene Corp. 36.28% 28.31% 24.61% 33.30% 28.43%
Eli Lilly & Co. 9.38% 16.30% 13.47% 13.56% 23.24%
Gilead Sciences Inc. 55.04% 58.87% 69.03% 62.37% 41.87%
Johnson & Johnson 24.07% 28.72% 25.05% 28.20% 25.77%
Merck & Co. Inc. 16.28% 13.51% 17.54% 13.42% 13.53%
Pfizer Inc. 25.92% 22.73% 24.20% 26.71% 29.44%
Regeneron Pharmaceuticals Inc. 35.41% 27.38% 30.51% 29.74% 36.11%
Operating Profit Margin, Sector
Pharmaceuticals & Biotechnology 23.68% 27.18% 26.43% 24.67% 23.77%
Operating Profit Margin, Industry
Health Care 16.14% 17.70% 17.41% 16.88% 16.25%

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × 5,344,200 ÷ 12,273,900 = 43.54%

Ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Biogen Inc.'s operating profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Net Profit Margin

Biogen Inc., net profit margin calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net income attributable to Biogen Inc. 2,539,100  3,702,800  3,547,000  2,934,784  1,862,341 
Revenues 12,273,900  11,448,800  10,763,800  9,703,324  6,932,199 
Ratio
Net profit margin1 20.69% 32.34% 32.95% 30.25% 26.87%
Benchmarks
Net Profit Margin, Competitors
Abbott Laboratories 1.74% 6.71% 21.68% 11.28% 11.79%
AbbVie Inc. 18.82% 23.22% 22.50% 8.89% 21.97%
Allergan PLC -25.88% 102.76% 25.98% -12.48% -8.65%
Amgen Inc. 9.08% 35.27% 33.13% 26.69% 27.93%
Bristol-Myers Squibb Co. 4.85% 22.94% 9.45% 12.62% 15.64%
Celgene Corp. 22.66% 17.87% 17.49% 26.44% 22.79%
Eli Lilly & Co. -0.89% 12.90% 12.07% 12.19% 20.27%
Gilead Sciences Inc. 18.03% 45.07% 56.32% 49.44% 28.46%
Johnson & Johnson 1.70% 23.01% 21.99% 21.96% 19.40%
Merck & Co. Inc. 5.97% 9.85% 11.25% 28.22% 10.00%
Pfizer Inc. 40.55% 13.66% 14.25% 18.42% 42.65%
Regeneron Pharmaceuticals Inc. 20.41% 18.42% 15.50% 12.34% 20.16%
Net Profit Margin, Sector
Pharmaceuticals & Biotechnology 11.23% 24.60% 22.73% 20.93% 21.77%
Net Profit Margin, Industry
Health Care 8.69% 14.91% 14.07% 13.46% 13.91%

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Net profit margin = 100 × Net income attributable to Biogen Inc. ÷ Revenues
= 100 × 2,539,100 ÷ 12,273,900 = 20.69%

Ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Biogen Inc.'s net profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Return on Equity (ROE)

Biogen Inc., ROE calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net income attributable to Biogen Inc. 2,539,100  3,702,800  3,547,000  2,934,784  1,862,341 
Total Biogen Inc. shareholders' equity 12,612,800  12,140,100  9,372,800  10,809,010  8,620,242 
Ratio
ROE1 20.13% 30.50% 37.84% 27.15% 21.60%
Benchmarks
ROE, Competitors
Abbott Laboratories 1.54% 6.82% 20.85% 10.61% 10.23%
AbbVie Inc. 104.16% 128.41% 130.39% 101.84% 91.90%
Allergan PLC -5.59% 19.65% 5.11% -5.76% -7.87%
Amgen Inc. 7.84% 25.85% 24.71% 20.01% 23.00%
Bristol-Myers Squibb Co. 8.58% 27.55% 10.97% 13.49% 16.91%
Celgene Corp. 42.48% 30.29% 27.07% 30.65% 25.94%
Eli Lilly & Co. -1.76% 19.54% 16.53% 15.55% 26.57%
Gilead Sciences Inc. 22.64% 71.48% 97.70% 78.45% 27.05%
Johnson & Johnson 2.16% 23.49% 21.66% 23.40% 18.68%
Merck & Co. Inc. 6.97% 9.78% 9.94% 24.50% 8.85%
Pfizer Inc. 29.88% 12.12% 10.75% 12.81% 28.83%
Regeneron Pharmaceuticals Inc. 19.51% 20.13% 17.40% 13.69% 21.74%
ROE, Sector
Pharmaceuticals & Biotechnology 11.00% 22.76% 19.94% 20.07% 20.31%
ROE, Industry
Health Care 12.09% 20.08% 17.51% 18.41% 18.69%

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 ROE = 100 × Net income attributable to Biogen Inc. ÷ Total Biogen Inc. shareholders' equity
= 100 × 2,539,100 ÷ 12,612,800 = 20.13%

Ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders' equity. Biogen Inc.'s ROE deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Return on Assets (ROA)

Biogen Inc., ROA calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net income attributable to Biogen Inc. 2,539,100  3,702,800  3,547,000  2,934,784  1,862,341 
Total assets 23,652,600  22,876,800  19,504,800  14,316,559  11,863,335 
Ratio
ROA1 10.73% 16.19% 18.19% 20.50% 15.70%
Benchmarks
ROA, Competitors
Abbott Laboratories 0.63% 2.66% 10.72% 5.53% 6.00%
AbbVie Inc. 7.50% 9.01% 9.70% 6.44% 14.14%
Allergan PLC -3.49% 11.61% 2.88% -3.10% -3.30%
Amgen Inc. 2.48% 9.95% 9.69% 7.47% 7.68%
Bristol-Myers Squibb Co. 3.00% 13.22% 4.93% 5.94% 6.64%
Celgene Corp. 9.75% 7.12% 5.92% 11.53% 10.84%
Eli Lilly & Co. -0.45% 7.05% 6.77% 6.43% 13.29%
Gilead Sciences Inc. 6.58% 23.70% 34.93% 34.91% 13.67%
Johnson & Johnson 0.83% 11.71% 11.55% 12.45% 10.42%
Merck & Co. Inc. 2.72% 4.11% 4.36% 12.12% 4.17%
Pfizer Inc. 12.40% 4.20% 4.16% 5.40% 12.78%
Regeneron Pharmaceuticals Inc. 13.67% 12.84% 11.34% 8.99% 14.38%
ROA, Sector
Pharmaceuticals & Biotechnology 4.19% 9.23% 8.58% 9.14% 9.39%
ROA, Industry
Health Care 4.69% 8.14% 7.43% 8.24% 8.60%

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 ROA = 100 × Net income attributable to Biogen Inc. ÷ Total assets
= 100 × 2,539,100 ÷ 23,652,600 = 10.73%

Ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Biogen Inc.'s ROA deteriorated from 2015 to 2016 and from 2016 to 2017.

Top